Amgen Inc. Q1 2007 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2007. Amgen Inc. is a global biotechnology company discovering, developing, and marketing human therapeutics. The company operates in a single segment: human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta/NEUPOGEN, and ENBREL. The financial statements are unaudited but include all normal recurring accruals.
Key Financial Metrics
| Metric (in millions) | Q1 2007 | Q1 2006 |
|---|---|---|
| Total Revenues | $3,687 | $3,217 |
| Product Sales | $3,565 | $3,127 |
| Operating Income | $1,400 | $1,234 |
| Net Income | $1,111 | $1,001 |
| Diluted EPS | $0.94 | $0.82 |
| Operating Cash Flow | $893 | $1,183 |
| Cash & Marketable Securities | $4,837 | $6,277 (Dec 31, 2006) |
| Total Debt Outstanding | $7,314 | $9,012 (Dec 31, 2006) |
Margins: Operating income as a percentage of product sales was 39% for both Q1 2007 and Q1 2006. The effective tax rate was 20.3% in Q1 2007, compared to 23.8% in Q1 2006.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 15% year-over-year, driven primarily by product sales growth of 14%. Key drivers included Aranesp (+14%), Neulasta/NEUPOGEN (+14%), and ENBREL (+11%).
- Expense Increases: Research and Development (R&D) expenses rose 30% to $851 million, primarily due to increased "mega-site" clinical trials. Selling, General, and Administrative (SG&A) expenses increased 12% to $770 million, largely reflecting profit sharing with Wyeth for ENBREL.
- Debt Reduction: On March 2, 2007, Amgen repurchased approximately 96% of its 2032 Modified Convertible Notes ($2.25 billion principal) for $1.702 billion in cash. This resulted in a $51 million write-off of deferred financing costs, impacting interest expense.
- Stock Repurchases: The company repurchased 8.8 million shares for $537 million in Q1 2007, compared to 46.6 million shares for $3.374 billion in Q1 2006.
Outlook, Risks, and Management Commentary
Regulatory and Safety Challenges (ESAs): Significant headwinds face Aranesp and EPOGEN due to safety concerns regarding Erythropoiesis-Stimulating Agents (ESAs). The FDA approved a boxed warning for the ESA class in March 2007. Consequently, nearly all Medicare contractors stopped reimbursing Aranesp for Anemia of Cancer (AoC). The Centers for Medicare and Medicaid Services (CMS) initiated a National Coverage Analysis (NCA) for ESAs in non-renal applications.
Competitive Landscape: Aranesp and EPOGEN face potential competition from Roche's peg-EPO (expected launch in 2007) and biosimilars in the EU. ENBREL continues to face share loss to competitors like HUMIRA and Remicade.
Product Specifics:
- Vectibix: Amgen discontinued treatment in the PACCE trial for metastatic colorectal cancer due to safety and efficacy data, though registrational studies continue.
- Neulasta/NEUPOGEN: Growth driven by segment expansion and conversion to Neulasta, though biosimilar competition is anticipated in the EU in 2007-2008.
Guidance: Management expects R&D expenses to grow in 2007 but not to the extent of 2006. However, they may defer or cancel planned trials if future sales of Aranesp and EPOGEN are negatively impacted by regulatory events. Operating expense growth is being managed to offset potential revenue declines.
Investor Verification Checklist
- ESA Reimbursement Impact: Verify the extent of revenue erosion from the loss of Medicare coverage for Aranesp in the Anemia of Cancer setting and the outcome of the CMS National Coverage Analysis.
- Roche Litigation: Monitor the status of the patent infringement lawsuit against Roche regarding peg-EPO and the potential impact of its 2007 launch.
- Legal Proceedings: Review updates on shareholder derivative suits filed in May 2007 alleging off-label marketing and failure to disclose negative clinical study results.
- Manufacturing Capacity: Assess risks related to the Puerto Rico facility, which handles formulation, fill, and finish for most principal products, including potential disruptions from natural disasters or supply chain issues.
- Debt Structure: Confirm the remaining balance of the 2032 Modified Convertible Notes ($80 million carrying value) and the terms of the remaining convertible debt.